NeoNeuro at CTAD 2018

We will be attending the 11th Clinical Trials on Alzheimer’s Disease (CTAD)

Poster LBP26

October 24th. to October 27 th., 2018

Barcelona
Spain
Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

November 2017

NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel to work with the INSIGHT cohort for the application of the Aptamarker platform to pre-AD samples. The INSIGHT cohort is an innovative study of Alzheimer’s disease, and one of the first in the world to monitor healthy subjects at-risk. NeoNeuro are using this cohort to extend their validation of the Aptamarker platform for Alzheimer’s disease to the diagnosis of amyloid status in healthy elderly subjects.

INSIGHT is made possible through an innovative new scheme in medical research, a multi-partner foundation that focuses the Investissements d’Avenir (Investment for the Future) programme via IHU-A-ICM and Pfizer, together with the teams at IM2A and ICM, on a shared objective, that of better understanding Alzheimer’s disease. INSIGHT is an ancillary study of the MEMENTO national cohort.

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

October 2017

bioeurope 2017

NeoNeuro will be attending BIO-Europe 2017. Dr. Penner will be available for meetings through the conference partnering portal

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

September 2017

bluedil logo1

NeoNeuro is pleased to announce that they have contracted BlueDil as a supporting partner in their quest to raise seed financing.  BlueDil co-founders ,Dominique Corneillo and Sylvain Forget, bring a combined 60 years of experience in the pharmaceutical industry involving all aspects of the health science ecosystem. NeoNeuro has developed a novel platform (Aptamarkers) for the stratification of patients of Alzheimer’s disease based on blood samples. The Aptamarker platform is based on next generation sequence analysis of selected aptamer libraries applied to individual blood samples. Financing is being sought on an equity investment level as well as strategic partnerships with pharma.

For more information regarding NeoNeuro please contact, Dr. Gregory Penner at gpenner@neoneuro-aptamers.com

For more information regarding BlueDil please contact the cofounders at dominique@bluedil.fr or sylvain@bluedil.fr

 

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

June 2017

aibl logo

NeoNeuro SAS and the Institut du cerveau et de la moelle épinière (ICM) are pleased to announce a collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)  group. The collaboration is focused on exploring the potential of an innovative diagnostic platform developed by NeoNeuro called Aptamarkers, for the diagnosis of Alzheimer’s disease in blood serum. NeoNeuro, a subsidiary of the Canadian aptamer company, NeoVentures Biotechnology Inc. developed this platform within the IPEPs incubator at ICM in Paris. The platform provides deep fingerprints of pathology specific epitopes on a real time, quantitative basis. This research has potential to enable a biochemical basis to characterize the effect of Alzheimer’s disease on a personalized basis. Results from an initial pilot study on 100 samples are expected by the fall of 2017.

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

October 2016

bioeuropeDr. Gregory Penner will be presenting our opportunity at Bio-Europe 2016. Please join us on Wednesday November 9th. at 10:00 am room: Rheinsaal 2 on level 2

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

December 2015

NeoNeuro has received a new grant from BPIfrance Financement, CMI- Amorcage 2 to continue our research towards the development of aptamers as diagnostic and therapeutic tools for Alzheimer’s disease.bpifrance_rvb_fd_blanc

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

September 2015

bpifrance_rvb_fd_blancNeoNeuro has been granted support from BPIfrance Financement under the PIA-1 program for the use of aptamers as a diagnostic and therapeutic tools in Alzheimer’s disease.

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail